CSL names McKenzie as new CEO

CSL names McKenzie as new CEO

Blood merchandise large CSL has appointed Paul McKenzie as chief govt, who will take over following CEO Paul Perreault’s decade of management.

The former chief working officer will tackle the brand new position in March, and Mr Perreault will stay with the corporate till his retirement in September.

After spending 25 years on the biotech business and 10 years on the helm, the outgoing CEO mentioned he was assured in Dr McKenzie’s management.

“Leading CSL during the last decade has been a privilege as we grew, innovated, and globalised to new levels, all while fostering a values-based culture focused on our promise to patients and public health around the world,” Mr Perreault mentioned.

The firm was the nationwide chief within the manufacturing of AstraZeneca’s COVID-19 vaccine after it was contracted by the Australian authorities to provide 50 million doses of the vaccine at its Victorian plant.

Dr McKenzie has been with CSL since 2019 and has 30 years of expertise in senior roles in analysis and improvement and manufacturing for Johnson & Johnson, Bristol-Myers Squibb and Merck.

CSL chair Brian McNamee mentioned Dr McKenzie’s expertise put him in good stead to guide the organisation.

“Paul McKenzie is a patient-focused global leader with a demonstrated track record of leading complex organisations and delivering outstanding business results,” Dr McNamee mentioned.

Dr McKenzie mentioned he was humbled and excited to take the reigns of Australia’s third-biggest firm.

“CSL’s promise to save people’s lives through science has long distinguished our company,” he mentioned.